MRD Detection Methods for Multiple Myeloma

Recruiting in Palo Alto (17 mi)

Andrzej Jakubowiak, MD, PhD - UChicago ...

Overseen byAndrzej Jakubowiak, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Chicago

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is to assess for Measurable Residual Disease (MRD) in multiple myeloma at a deeper level than what is currently available by combining novel imaging and laboratory techniques, determine if patients who are MRD-negative by these multiple modalities can safely and effectively discontinue post-transplant maintenance therapy, and determine if liquid biopsies is a more accurate and/or less invasive sampling technique for multiple myeloma. The purpose of this research is to determine if patients who are MRD-negative by multiple modalities ("multimodality MRD-negative") can safely and effectively discontinue post-transplant maintenance therapy (single agent lenalidomide, pomalidomide, bortezomib, or ixazomib) after receiving at least one year of maintenance therapy.

Research Team

Andrzej Jakubowiak, MD, PhD

Principal Investigator

University of Chicago

Eligibility Criteria

This trial is for adults over 18 with multiple myeloma who've had initial treatment and at least a year of maintenance therapy without signs of active disease. They must be in good health, able to undergo bone marrow tests, and women must use contraception if necessary.

Inclusion Criteria

I agree to use two reliable birth control methods or abstain from sex if I can have children and am on lenalidomide.

I can take care of myself but might not be able to do heavy physical work.

My last PET/CT scan was within 1.5 years and showed no signs of myeloma.

See 9 more

Exclusion Criteria

I have been diagnosed with or suspected to have amyloidosis.

I am not willing to stop my ongoing maintenance therapy.

I have a blood cancer along with my current condition.

See 5 more

Treatment Details

Interventions

Discontinuation Phase (Device)
Screening Phase (Other)

Trial OverviewThe study aims to see if patients with no measurable residual disease can stop their post-transplant maintenance therapy safely. It uses advanced imaging and lab tests including PET/CT scans, flow cytometry, NGS, and mass spectrometry.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: MRD2STOP ARMExperimental Treatment2 Interventions